| Literature DB >> 35406227 |
Sara Garcinuño1, Inmaculada Aranaz1,2, Concepción Civera2, Concepción Arias2, Niuris Acosta1,2.
Abstract
In this work, two chitosan samples from cuttlebone and squid pen are produced and characterized. We studied the formation of thermoresponsive hydrogels with β-glycerol phosphate and found proper formulations that form the hydrogels at 37 °C. Gel formation depended on the chitosan source being possible to produce the thermoresponsive hydrogels at chitosan concentration of 1% with cuttlebone chitosan but 1.5% was needed for squid pen. For the first time, these non-commercial chitosan sources have been used in combination with β-glycerol phosphate to prepare risperidone formulations for controlled drug delivery. Three types of formulations for risperidone-controlled release have been developed, in-situ gelling formulations, hydrogels and xerogels. The release profiles show that in-situ gelling formulations and particularly hydrogels allow an extended control release of risperidone while xerogels are not appropriate formulations for this end since risperidone was completely released in 48 h.Entities:
Keywords: chitosan; controlled release; hydrogels; injectable formulation; risperidone; xerogels; β-chitin
Year: 2022 PMID: 35406227 PMCID: PMC9002647 DOI: 10.3390/polym14071355
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Risperidone formulations.
| Formulation | Gelation Time, (h) | Site of Gelation | Freeze-Drying |
|---|---|---|---|
| Injectable | 0 | Dialysis Membrane 1 | No |
| Hydrogel | 5 | Eppendorf tube | No |
| Xerogel | 5 | Syringe 1 mL | Yes |
1 Dialysis membrane of 7000 Da.
Figure 1Optical visualization of chitosan samples. Squid pen chitosan (left) and cuttlebone chitosan (right).
Chitosan Characterization.
| Property | Cuttlebone Chitosan | Squid Pen Chitosan |
|---|---|---|
| Humidity (%) | 7.76 ± 0.06 | 5.50 ± 0.14 |
| Ash content (%) | 1.65 ± 0.01 | 0.22 ± 0.01 |
| Acetylation Degree (%) | 7.53 ± 0.01 | 5.93 ± 0.01 |
| Intrinsic viscosity (g/dL) | 1.20 ± 0.15 | 6.63 ± 0.11 |
| Mv (kDa) | 16 ± 3 | 153 ± 3 |
Figure 2XRD pattern of squid pen chitosan (A) and cuttlebone chitosan (B).
Figure 3FTIR-ATR spectra of cuttlebone chitosan (A) and squid pen chitosan (B). Regions I, II and III are indicated in the figure.
Thermal gelation of chitosan solutions with beta glycerol phosphate at 37 °C.
| % βGP | % Squid Pen Chitosan | % Cuttlebone Chitosan | ||||
|---|---|---|---|---|---|---|
| 0.5% | 1% | 1.5% | 0.5% | 1% | 1.5% | |
| 5% | - | - | 10 min | - | - | 30 min |
| 10% | - | - | 5 min | - | 10 min | 10 min |
| 15% | - | - | 2 min | - | 5 min | 5 min |
- No gelation occurs.
Figure 4Risperidone formulations.
Figure 5XRD patterns of Risperidone (A), glycerolphosphate (B), xerogel from cuttlebone chitosan (C) and xerogel from squid pen chitosan (D).
Figure 6SEM images of xerogels from cuttlebone (A,B) and squid pen chitosan (C,D).
Figure 7Cumulative release of risperidone from different formulations: (A) Hydrogels, (B) Injectables, (C) Xerogels.
Selected models applied for the evaluation of RSP release and statistical parameters.
| Model | Equation | Parameters | HSp | HC | ISp | IC |
|---|---|---|---|---|---|---|
| Korsmeyer–Peppas |
| 0.45 | 0.354 | 0.291 | 0.145 | |
|
| 8.87 | 12.693 | 0.515 | 36.522 | ||
| AIC | 30.53 | 35.975 | 5.840 | 43.500 | ||
| R2 | 0.986 | 0.979 | 0.989 | 0.974 | ||
| Higuchi |
|
| 0.13 | 0.110 | 0.250 | DNF |
| AIC | 47.36 | 51.885 | 0.828 | |||
| R2 | 0.936 | 0.845 | 111.967 | |||
| Weibul model |
|
| 0.005 | 0.005 | 0.004 | 0.779 |
| Td | 0.18 | 0.159 | 0.304 | 1.989 | ||
| AIC | 72.35 | 71.862 | 111.967 | 111.076 | ||
| R2 | 0.927 | 0.901 | 0.828 | 0.837 | ||
| 1st order |
| K | 0.025 | 0.030 | 0.014 | 0.425 |
| AIC | 71.080 | 70.828 | 109.631 | 92.884 | ||
| R2 | 0.923 | 0.893 | 0.832 | 0.834 |
HSp—Hydrogel squid pen, HC—Hydrogel cuttlebone, ISp—Injectable squid pen, IC—Injectable cuttlebone, DNF: Data not fit.